Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis

Clinics

Volumn 70, Issue 7, 2015, Pages 524-530

  Yin, Yongmei ^a   Wang, Jun ^a   Wang, Xuedong ^a   Gu, Lan ^a   Pei, Hao ^a   Kuai, Shougang ^a   Zhang, Yingying ^a   Shang, Zhongbo ^a  

^a JIANGNAN UNIVERSITY   (China)

Author keywords

Lung cancer; Meta analysis; NLR; Overall survival

Indexed keywords

HUMAN; LUNG TUMOR; LYMPHOCYTE; LYMPHOCYTE COUNT; META ANALYSIS; MORTALITY; NEUTROPHIL; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; SMALL CELL LUNG CANCER;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES; NEUTROPHILS; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

EID: 84937957993     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2015(07)10     Document Type: Review

References (38)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013; 63(1): 11-30, http://dx. doi. org/10. 3322/caac. v63. 1.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90, http://dx. doi. org/10. 3322/caac. v61: 2.
3. Gail MH, Eagan RT, Feld R, Ginsberg R, Goodell B, Hill L, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer. 1984; 54(9): 1802-13, http://dx. doi. org/10. 1002/(ISSN)1097-0142.
4. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predictsurvival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapyregimens based on eastern cooperative oncology group data. J Clin Oncol. 2005; 23(1): 175-83, http://dx. doi. org/10. 1200/JCO. 2005. 04. 177.
5. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005; 127(3): 978-83, http://dx. doi. org/10. 1378/chest. 127. 3. 978.
6. Riquet M, Bagan P, Le Pimpec Barthes F, Banu E, Scotte F, Foucault C, et al. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg. 2007; 84(6): 1818-24, http://dx. doi. org/10. 1016/j. athoracsur. 2007. 07. 015.
7. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009; 374(9687): 379-86, http://dx. doi. org/10. 1016/S0140-6736 (09)60737-6.
8. Gu X, Ma C, Yuan D, Song Y. Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review. Transl Lung Cancer Res. 2012; 1(1): 36-44.
9. Tanner NT, Sherman CA, Silvestri GA. Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. Transl Lung Cancer Res. 2012; 1(2): 96-8.
10. Donnem T, Bremnes RM, Busund LT, Andersen S, Pezzella F. Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis. 2012; 4(2): 212-3.
11. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203): 436-44, http://dx. doi. org/10. 1038/nature07205.
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646-74, http://dx. doi. org/10. 1016/j. cell. 2011. 02. 013.
13. Lin X, Li W, Lai J, Okazaki M, Sugimoto S, Yamamoto S, et al. Five-year update on the mouse model of orthotopic lung transplantation: scientific uses, tricks of the trade, and tips for success. J Thorac Dis. 2012; 4(3): 247-58.
14. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331 (6024): 1565-70, http://dx. doi. org/10. 1126/science. 1203486.
15. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010; 6(1): 149-63, http://dx. doi. org/10. 2217/fon. 09. 136.
16. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005; 91(3): 181-4, http://dx. doi. org/10. 1002/(ISSN)1096-9098.
17. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012; 19(1): 217-24, http://dx. doi. org/10. 1245/s10434-011-1814-0.
18. Gwak MS, Choi SJ, Kim JA, Ko JS, Kim TH, Lee SM, et al. Effects of gender on white blood cell populations and neutrophil-lymphocyte ratio following gastrectomy in patients with stomach cancer. J Korean Med Sci. 2007; 22(Suppl): S104-8, http://dx. doi. org/10. 3346/jkms. 2007. 22. S. S104.
19. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI et al. Elevated preoperative neutrophil: lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011; 18(12): 3362-9, http://dx. doi. org/10. 1245/s10434-011-1754-8.
20. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 7(8): 16, http://dx. doi. org/10. 1186/1745-6215-8-16.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-88, http://dx. doi. org/10. 1016/0197-2456(86)90046-2.
22. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4): 719-48.
23. Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil counts as an independent prognostic factor in advanced non-small cell lung cancer-an analysis of Japan multinational trial organization LC00-03. Eur J Cancer. 2009; 45(11): 1950-8, http://dx. doi. org/10. 1016/j. ejca. 2009. 01. 023.
24. Kacan T, Babacan NA, Seker M, Yucel B, Bahceci A, Eren AA, et al. Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? Asian Pac J Cancer Prev. 2014; 15(5): 2089-94, http://dx. doi. org/10. 7314/APJCP. 2014. 15. 5. 2089.
25. Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratios associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2013; 62(3): 471-9, http://dx. doi. org/10. 1007/s00262-012-1347-9.
26. Lee Y, Kim SH, Han JY, Kim HT, Yun T, Soo LJ. Early neutrophil-tolymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapyas first-line therapy. J Cancer Res Clin Oncol. 2012; 138(12): 2009-16, http://dx. doi. org/10. 1007/s00432-012-1281-4.
27. Wang X, Jiang R, Li K. Prognostic significance of pretreatment laboratory parameters in Combined Small-Cell Lung Cancer. Cell Biochem Biophys. 2014; 69(3): 633-40, http://dx. doi. org/10. 1007/s12013-014-9845-3.
28. Cedrés S, Torrejon D, Martínez A, Martinez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012; 14(11): 864-9, http://dx. doi. org/10. 1007/s12094-012-0872-5.
29. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev. 2013; 14(9): 5237-42, http://dx. doi. org/10. 7314/APJCP. 2013. 14. 9. 5237.
30. Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA. Prognostic performance of inflammation based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer. 2014; 110(8): 1930-5, http://dx. doi. org/10. 1038/bjc. 2014. 145.
31. Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014; 111(3): 452-460, http://dx. doi. org/10. 1038/bjc. 2014. 317.
32. Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H, et al. T Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer. J Thorac Oncol 2015; 10(2): 280-285, http://dx. doi. org/10. 1097/JTO. 0000000000000399.
33. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res. 2011; 31(9): 2995-8.
34. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc. Surg 2009; 137(2): 425-8.
35. Liao Y, Ni Y, He R, Liu W, Du J. Clinical implications of fibroblast activation protein-a in non-small cell lung cancer after curative resection: a new predictor for prognosis. J Cancer Res Clin Oncol. 2013; 139(9): 1523-8, http://dx. doi. org/10. 1007/s00432-013-1471-8.
36. Tomita M, Shimizu T, Ayabe T, Nakamura K, Onitsuka T. Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res. 2012; 32(8): 3535-8.
37. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014; 15(11): e493-503, http://dx. doi. org/10. 1016/S1470-2045(14)70263-3.
38. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012; 12(4): 253-68, http://dx. doi. org/10. 1038/nri3175.